Efficacy and safety of STS101 DHE nasal powder for the acute treatment of migraine: Results from the Phase 3 double-blind, randomized, placebo-controlled SUMMIT study

被引：0
|
作者：
Lipton, R. [1 ]
Tepper, S. [2 ]
Albrecht, D. [3 ]
机构：
[1] Albert Einstein Coll Med, Bronx, NY USA
[2] Geisel Sch Med, Lebanon, NH USA
[3] Satsuma Pharmaceut, South San Francisco, CA USA
来源：
HEADACHE | 2023年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-70
引用
收藏
页码：112 / 113
页数：2
相关论文
共 50 条
  • [1] Sustained efficacy of STS101 DHE Nasal Powder for the acute treatment of migraine: Results from the Phase 3 double-blind, randomized, placebo-controlled SUMMIT study
    Rapoport, A.
    Spierings, E.
    Albrecht, D.
    [J]. HEADACHE, 2023, 63 : 170 - 170
  • [2] Efficacy of STS101 DHE Nasal Powder for the acute treatment of difficult to treat migraines: Results from the Phase3 double-blind, randomized, placebo controlled SUMMIT study
    Ailani, J.
    Cowan, R.
    Albrecht, D.
    [J]. HEADACHE, 2023, 63 : 136 - 137
  • [3] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, K.
    Croop, R.
    Pavlovic, J.
    Mosher, L.
    Smith, T.
    Madonia, J.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [4] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena
    Mosher, Linda
    Smith, Timothy
    Madonia, Jennifer
    Lovegren, Meghan
    Lipton, Richard
    [J]. NEUROLOGY, 2023, 100 (17)
  • [5] Efficacy and safety of zavegepant nasal spray for the acute treatment of migraine: Results of a phase 3 double-blind, randomized, placebo controlled trial
    Mullin, K.
    Croop, R.
    Pavlovic, J. M.
    Mosher, L.
    Smith, T. R.
    Madonia, J.
    Lovegren, M.
    Coric, V
    Lipton, R. B.
    [J]. HEADACHE, 2022, 62 : 128 - 129
  • [6] Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial
    Mullin, Kathleen
    Croop, Robert
    Pavlovic, Jelena M.
    Mosher, Linda
    Smith, Timothy R.
    Madonia, Jennifer
    Lovegren, Meghan
    Coric, Vladimir
    Lipton, Richard B.
    [J]. CEPHALALGIA, 2022, 42 (1_SUPPL) : 126 - 127
  • [7] Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
    Goadsby, Peter J.
    Wietecha, Linda A.
    Dennehy, Ellen B.
    Kuca, Bernice
    Case, Michael G.
    Aurora, Sheena K.
    Gaul, Charly
    [J]. BRAIN, 2019, 142 : 1894 - 1904
  • [8] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
    Takeshima, Takao
    Sakai, Fumihiko
    Hirata, Koichi
    Imai, Noboru
    Matsumori, Yasuhiko
    Yoshida, Ryuji
    Peng, Cheng
    Cheng, Sunfa
    Mikol, Daniel D.
    [J]. HEADACHE, 2021, 61 (06): : 927 - 935
  • [9] Efficacy of phenazone in the treatment of acute migraine attacks:: a double-blind, placebo-controlled, randomized study
    Göbel, H
    Heinze, A
    Niederberger, U
    Witt, T
    Zumbroich, V
    [J]. CEPHALALGIA, 2004, 24 (10) : 888 - 893
  • [10] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
    Croop, R.
    Lipton, R. B.
    Kudrow, D.
    Stock, D. A.
    Kamen, L.
    Conway, C. M.
    Stock, E. G.
    Coric, V.
    Goadsby, P. J.
    [J]. CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29
12345